Company: PTPI
Filing Date: 2025-03-07
Form Type: PRE 14A
Source: 0001104659-25-021794
Chunk: 2

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-03-07
Form: PRE 14A
Chunk 2
---
 encourage you to vote
your shares electronically via the Internet or by completing and returning your proxy card prior to the Special Meeting, in order for
your shares to be represented and voted at the Special Meeting. If your shares are held in the name of a broker, trust, bank or other
nominee, and you receive these materials through your broker or through another intermediary, please complete and return the materials
in accordance with the instructions provided to you by such broker or other intermediary or contact your broker directly in order to obtain
a proxy issued to you by your nominee holder to attend the meeting and vote in person. Failure to do so may result in your shares not
being eligible to be voted by proxy at the Special Meeting.

We urge you to read the accompanying
Notice and Proxy Statement carefully and vote in accordance with the Board’s recommendations on all proposals.

Thank you for your continued
support of Petros Pharmaceuticals, Inc. We look forward to seeing you at the Special Meeting.

Sincerely,

Joshua Silverman,
Chairman of the Board

| IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE                                         
 STOCKHOLDER MEETING TO BE HELD ON THURSDAY, APRIL 10, 2025:                                                    |
|:---------------------------------------------------------------------------------------------------------------|
| Our official Notice of Special Meeting of Stockholders and Proxy Statement are available at: www.proxyvote.com |

<div align='center'>NOTICE OF 2025 SPECIAL MEETING OF STOCKHOLDERS OF
PETROS PHARMACEUTICALS, INC.</div>

[ ], 2025

TIME: 10 a.m. Eastern Time
DATE: April 10, 2025
PLACE: www.virtualshareholdermeeting.com/PTPI2025SM

Purposes:

| 1. | To approve, for purposes of complying with Nasdaq Listing Rule 5635(d),                                                           
 the issuance of shares of our common stock, par value $0.0001 per share (the “Common Stock”) underlying the Series A              
 warrants (the “Series A Warrants”) and Series B warrants (the “Series B Warrants” and, together                                   
 with the Series A Warrants, the “Series Warrants”) issued by us in a public offering transaction (the “Offering”)                 
 on February 19, 2025 (including shares of Common Stock issuable upon operation of certain anti-dilutions provisions applicable to 
 such Series Warrants, and shares of Common Stock issuable upon “alternative cash